Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30，Shanghai Unicar-Therapy Bio-medicine)

N/A

Report date: 2024/11/12 20:00:08

Base Information

Drug NameChimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30，Shanghai Unicar-Therapy Bio-medicine)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityB-lymphocyte antigen CD19 modulators +[6] 
TargetsB-lymphocyte antigen CD19CD22B-lymphocyte antigen CD20 +[4] 
Therapy Area/IndicationsPancreatic NeoplasmsLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesShanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Active IndicationsN/A
Inactive IndicationsPancreatic NeoplasmsLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A
Related LinksN/A